Fianlimab is a monoclonal antibody commercialized by Regeneron Pharmaceuticals, with a leading Phase III program in Squamous Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 18 clinical trials, of which 1 was completed, 11 are ongoing, and 6 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Fianlimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Fianlimab is expected to reach an annual total of $289 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Fianlimab Overview
Fianlimab is under development for the treatment of metastatic melanoma, acral lentiginous melanoma, non-small cell lung cancer, squamous non-small cell lung cancer, advanced hematological malignancies including lymphoma and solid tumors including breast cancer, breast cancer, lung cancer, melanoma, head and neck squamous cell carcinoma and thyroid cancer. The drug candidate acts by targeting the checkpoint inhibitor (LAG-3). The therapeutic candidate is developed based on VelociGene and VelocImmune platform technology. It is administered through intravenous route.
Regeneron Pharmaceuticals Overview
Regeneron Pharmaceuticals (Regeneron) discovers, develops, manufactures, and markets medicines for the treatment of serious medical conditions. Its products are focused on helping patients suffering from cancer, allergic and inflammatory diseases, eye diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, hematologic conditions, pain, and rare diseases. Regeneron develops products using its Trap and VelociSuite technology platforms, which include VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, and other related technologies. The company operates manufacturing facilities in Rensselaer, New York, and Limerick. It also collaborates with strategic partners to develop, manufacture and commercialize its products. The company sells its products to specialty pharmacies and distributors. It operates in the US, the Netherlands, Bermuda, Ireland, Spain, India, Japan and the UK. Regeneron is headquartered in Tarrytown, New York, the US.
The company reported revenues of (US Dollars) US$13,117.2 million for the fiscal year ended December 2023 (FY2023), an increase of 7.8% over FY2022. In FY2023, the company’s operating margin was 30.9%, compared to an operating margin of 38.9% in FY2022. In FY2023, the company recorded a net margin of 30.1%, compared to a net margin of 35.6% in FY2022.
The company reported revenues of US$3,145 million for the first quarter ended March 2024, a decrease of 8.4% over the previous quarter.
For a complete picture of Fianlimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
